Department of Basic and Clinical Neuroscience, King's College London, Institute of Psychiatry, Psychology and Neuroscience, The Maurice Wohl Clinical Neuroscience Institute, Cutcombe Road, London, SE5 9RT, UK.
Parkinson's Foundation Center of Excellence, King's College Hospital, London, UK.
J Neural Transm (Vienna). 2023 Jul;130(7):925-930. doi: 10.1007/s00702-023-02603-y. Epub 2023 Apr 10.
To evaluate the long-term, real-life effects on non-motor symptoms (NMS) of opicapone compared to entacapone in levodopa-treated people with Parkinson's disease (PwP).
A retrospective data analysis, with pre- and post-opicapone initiation data of 17 PwP with motor fluctuations compared to a comparable group of 18 PwP introduced on entacapone. The primary outcome was changes in the NMS Scale (NMSS) total score after 1-year follow-up. Secondary outcomes included changes in the NMSS domains, and Parkinson's Disease Sleep Scale (PDSS) total and item scores after the same time span.
Groups were comparable for baseline demographics and Parkinson's-related features (p ≥ 0.314) as well as duration of follow-up (1.33 ± 0.66 years for PwP on opicapone and 1.23 ± 0.49 years for those on entacapone; p = 0.858). PwP who were introduced on opicapone showed no changes in NMSS and PDSS total scores after 1 year (p = 0.605 and p = 0.507, respectively), whereas PwP who were introduced on entacapone showed significant worsening of NMSS and PDSS total scores at follow-up (p = 0.005 and p = 0.001, respectively). In neither group changes in individual NMSS domains from baseline to follow-up were observed (p ≥ 0.288 for entacapone and p ≥ 0.816 for opicapone, respectively). In PwP on entacapone significant worsening was seen in the distressing dreams, hallucinations, and limb numbness items of the PDSS (p ≤ 0.05).
Introduction of opicapone in real-life PwP with motor fluctuations seems to stabilise NMS burden and aspects of sleep dysfunction, in contrast to entacapone where there was a worsening of NMS burden and PDSS scores over 1 year follow-up.
评估与恩他卡朋相比，在左旋多巴治疗的帕金森病（PD）患者中使用阿扑吗啡酮对非运动症状（NMS）的长期实际影响。
对 17 名有运动波动的 PD 患者在使用阿扑吗啡酮治疗前后的数据进行回顾性分析，并与接受恩他卡朋治疗的 18 名可比患者的相应数据进行比较。主要结局为 1 年随访后 NMS 量表（NMSS）总分的变化。次要结局包括在同一时间段内 NMSS 各域和帕金森病睡眠量表（PDSS）总分和各条目评分的变化。
两组患者的基线人口统计学和与帕金森病相关的特征（p≥0.314）以及随访时间（使用阿扑吗啡酮的患者为 1.33±0.66 年，使用恩他卡朋的患者为 1.23±0.49 年；p=0.858）均具有可比性。使用阿扑吗啡酮治疗的患者在 1 年后 NMSS 和 PDSS 总分无变化（p=0.605 和 p=0.507），而使用恩他卡朋治疗的患者在随访时 NMSS 和 PDSS 总分明显恶化（p=0.005 和 p=0.001）。在两组患者中，从基线到随访时，NMSS 各域的变化均不明显（与恩他卡朋相比，p≥0.288，与阿扑吗啡酮相比，p≥0.816）。在接受恩他卡朋治疗的患者中，PDSS 的噩梦、幻觉和四肢麻木条目显著恶化（p≤0.05）。
在有运动波动的现实世界 PD 患者中引入阿扑吗啡酮似乎可稳定 NMS 负担和睡眠功能障碍的某些方面，而与恩他卡朋相比，在 1 年随访期间，NMS 负担和 PDSS 评分恶化。
